Radiopharmaceutical therapy delivers radiation directly to cancer cells, helping destroy them while limiting exposure to healthy tissue. This targeted approach can reduce side effects, improve outcomes, and make treatment easier to tolerate
Targeted Therapies for Effective Treatment
Our Radiopharma Treatment Options
Lutathera®
- FDA-approved for grade 1 neuroendocrine tumors not well controlled on lanreotide alone
- Approved as first-line therapy for grade 2–3 neuroendocrine tumors
Pluvicto®
- FDA-approved for second-line therapy after failing one ARPI
- Found to be more effective with fewer side effects compared to chemotherapy
- Delivered as a 30-minute infusion every six weeks for six sessions
- Our team monitors blood counts, kidney function, and manages side effects throughout treatment
Xofigo®
- FDA-approved for metastatic castration-resistant prostate cancer (mCRPC) patients with symptomatic bone metastases and no known visceral metastases
- Clinical studies showed an overall survival benefit (OS extended by 3.6 months in exploratory analysis)
- Administered as a 1-minute injection every four weeks for six sessions
Why Choose Akumin for Radiopharma?
Safe, convenient, patient-focused radiopharmaceutical therapy
Comprehensive Expertise
Decades of combined experience in both external beam radiation and systemic radiopharmaceutical therapy, delivering precise and effective treatments.
Decades of combined experience in both external beam radiation and systemic radiopharmaceutical therapy, delivering precise and effective treatments.
Patient-Focused Care
Close monitoring of safety, side effects, and progress to ensure treatments are well-tolerated and risks are minimized.
Close monitoring of safety, side effects, and progress to ensure treatments are well-tolerated and risks are minimized.
Recognized Excellence
Akumin-managed Personalized Radiation Oncology is designated as a Radiopharmaceutical Therapy Center of Excellence by the Society of Nuclear Medicine & Molecular Imaging, reflecting our commitment to the highest standards of care.
Akumin-managed Personalized Radiation Oncology is designated as a Radiopharmaceutical Therapy Center of Excellence by the Society of Nuclear Medicine & Molecular Imaging, reflecting our commitment to the highest standards of care.